Noregen™ (CTR-107) is a synthetic protein modeled after norrin, a naturally occurring protein that guides retinal formation in fetal development. It targets the progressive loss of the tiny capillary vessels and promotes their organized re-growth. The ultimate promise is to reverse vision loss in diseases affecting retinal and choroidal blood vessels.
Norrin performs these functions in the body:
We’ve found that Noregen™ (CTR-107) functions similarly. In mouse models it:
Noregen™ (CTR-107) is a unique, novel regenerative, retinal therapeutic that is derived from an endogenous human protein and is backed by solid in vitro and in vivo science. Noregen™ (CTR-107) addresses an urgent unmet need in patients with inherited or acquired retinal diseases. There is also exciting potential for expansion of Noregen’s™ (CTR-107) therapeutic range beyond retinal diseases.
On January 27, 2022 the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for Noregen™ (CTR-107), the first potential regenerative therapy for the treatment of Familial Exudative Vitreoretinopathy (FEVR) associated vision loss. Read the press release here.
For more information about Noregen™ (CTR-107) or our science email us at email@example.com
As a company dedicated to pursuit of regenerative medicine approaches for sensory-related diseases, Caeregen Therapeutics applies leading-edge science and technologies to the discovery and development of novel therapies to repair, restore, and protect diseased or damaged sensory and neurologic structures.